ANXA1 and breast carcinoma: Studies in breast cancer have found that in the absence of detectable levels of P-glycoprotein and the breast cancer resistance protein, ANXA1 upregulation is associated with increased resistance to several anticancer drugs, including doxorubicin, melphalan, and etoposide (43).